RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.

abstract：INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

journal_title：Expert review of anticancer therapy

authors： Manceau C,Mourey L,Pouessel D,Ploussard G

更新日期：2020-08-01 00:00:00

abstract：:A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Cibula D,Zikan M

更新日期：2014-03-01 00:00:00

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00

abstract：:While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

journal_title：Expert review of anticancer therapy

authors： Dellinger TH,Monk BJ

更新日期：2009-07-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poo...

journal_title：Expert review of anticancer therapy

authors： Wardak Z,Choe KS

更新日期：2013-11-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

journal_title：Expert review of anticancer therapy

authors： Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Cancer genome sequencing studies have discovered mutations in members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex in nearly 25% of human cancers. The SWI/SNF complex, first discovered in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals, contains ...

journal_title：Expert review of anticancer therapy

authors： Orlando KA,Nguyen V,Raab JR,Walhart T,Weissman BE

更新日期：2019-05-01 00:00:00

abstract：:Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

journal_title：Expert review of anticancer therapy

authors： Macafee DA,Maxwell-Armstrong C,Scholefield JH

更新日期：2003-08-01 00:00:00

abstract：INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

journal_title：Expert review of anticancer therapy

authors： Bayar MA,Antoun S,Lanoy E

更新日期：2017-04-01 00:00:00

abstract：:Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

journal_title：Expert review of anticancer therapy

authors： Shapiro D,Tareen B

更新日期：2012-07-01 00:00:00

abstract：:Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

journal_title：Expert review of anticancer therapy

authors： Braun MS,Quirke P,Seymour MT

更新日期：2007-04-01 00:00:00

abstract：:Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

journal_title：Expert review of anticancer therapy

authors： Taplin ME

更新日期：2008-09-01 00:00:00

abstract：:A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting. There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas. Tw...

journal_title：Expert review of anticancer therapy

authors： Wen PY

更新日期：2010-09-01 00:00:00

abstract：:The year 2006 will mark a turning point in the daily management of patients with metastatic renal cell carcinoma. The impact of immunotherapy with interferon-alpha or interleukin-2 has been shown to be restricted to a minority of patients. The growing understanding of molecular mechanisms involved in the pathogenesis ...

journal_title：Expert review of anticancer therapy

authors： Pouessel D,Culine S

更新日期：2006-12-01 00:00:00

abstract：:Introduction: The microbiota is recognized for its impact on both human health and disease. The human microbiota is made up of trillions of cells, including bacteria, viruses, and fungi. The largest population of microbes reside in the gut, prompting research for better understanding of the impact of gastrointestinal ...

journal_title：Expert review of anticancer therapy

authors： Garajová I,Balsano R,Wang H,Leonardi F,Giovannetti E,Deng D,Peters GJ

更新日期：2020-12-08 00:00:00

abstract：:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

journal_title：Expert review of anticancer therapy

authors： Camara-Clayette V,Hermine O,Ribrag V

更新日期：2012-09-01 00:00:00

abstract：:Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer...

journal_title：Expert review of anticancer therapy

authors： Planchard D

更新日期：2011-08-01 00:00:00

abstract：:Fludarabine is a prodrug that is converted to the free nucleoside 9-beta-D-arabinosyl-2-fluoroadenine (F-ara-A), which enters cells and accumulates mainly as the 5'-triphosphate, F-ara-ATP. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. Collectively, these actions affect DNA synthes...

journal_title：Expert review of anticancer therapy

authors： Montillo M,Ricci F,Tedeschi A

更新日期：2006-09-01 00:00:00

abstract：:Prostate cancer is the most common solid-organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-re...

journal_title：Expert review of anticancer therapy

authors： Rawlinson A,Mohammed A,Beatty J,Bell R,Miller M

更新日期：2012-04-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

journal_title：Expert review of anticancer therapy

authors： Metro G,Crinò L

更新日期：2011-05-01 00:00:00

abstract：:Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

journal_title：Expert review of anticancer therapy

authors： Kelly C,Cassidy J

更新日期：2007-06-01 00:00:00

abstract：:The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

journal_title：Expert review of anticancer therapy

authors： Gore ME,Harrison ML,Montes A

更新日期：2007-01-01 00:00:00

abstract：:For many decades, the use of chemotherapy as second-line therapy in non-small-cell lung cancer relied upon disease progression. Several studies have shown that four to six cycles of chemotherapy administered as front-line therapy treatment offers a survival advantage to patients; however, further chemotherapy beyond t...

journal_title：Expert review of anticancer therapy

authors： Velez M,Belalcazar A,Domingo G,Blaya M,Raez LE,Santos ES

更新日期：2010-04-01 00:00:00

abstract：:Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contr...

journal_title：Expert review of anticancer therapy

authors： Tuttle T,Habermann E,Abraham A,Emory T,Virnig B

更新日期：2007-08-01 00:00:00

abstract：:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

journal_title：Expert review of anticancer therapy

authors： Vijayamurugan N,Bakhshi S

更新日期：2014-02-01 00:00:00

abstract：:Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

journal_title：Expert review of anticancer therapy

authors： Gordon MS

更新日期：2011-03-01 00:00:00

abstract：:According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

journal_title：Expert review of anticancer therapy

authors： Gabriel EM,Jatoi I

更新日期：2012-02-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：:Sophia Maprayil, Commissioning Editor for Expert Review of Anticancer Therapy, talks to Dr Iain Frame, Director of Research for Prostate Cancer UK. Iain is Prostate Cancer UK's first Director of Research, responsible for overseeing the development and implementation of the charity's ambitious new research strategy. He...

journal_title：Expert review of anticancer therapy

authors： Frame I,Maprayil S

更新日期：2014-11-01 00:00:00

abstract：:Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

journal_title：Expert review of anticancer therapy

authors： Sakatani T,Onyango P

更新日期：2003-12-01 00:00:00